Back to Search
Start Over
Regadenoson: A New Myocardial Stress Agent
- Source :
-
Journal of the American College of Cardiology (JACC) . Sep2009, Vol. 54 Issue 13, p1123-1130. 8p. - Publication Year :
- 2009
-
Abstract
- Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A2A agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vasodilator stress agent, currently the only approved selective A 2A agonist. [Copyright &y& Elsevier]
Details
- Language :
- English
- ISSN :
- 07351097
- Volume :
- 54
- Issue :
- 13
- Database :
- Academic Search Index
- Journal :
- Journal of the American College of Cardiology (JACC)
- Publication Type :
- Academic Journal
- Accession number :
- 44260813
- Full Text :
- https://doi.org/10.1016/j.jacc.2009.04.089